MAPK Cancer Research Results

MAPK, mitogen-activated protein kinase: Click to Expand ⟱
Source: CGL-CS
Type:
Mitogen-activated protein kinases (MAPKs) are a group of proteins involved in transmitting signals from the cell surface to the nucleus, playing a crucial role in various cellular processes, including growth, differentiation, and apoptosis (programmed cell death).

MAPK Pathways: The MAPK family includes several pathways, the most notable being:
1.ERK (Extracellular signal-Regulated Kinase): Often associated with cell proliferation and survival.
2.JNK (c-Jun N-terminal Kinase): Typically involved in stress responses and apoptosis.
3.p38 MAPK: Associated with inflammatory responses and apoptosis.

Inhibitors: Targeting the MAPK pathway has become a strategy in cancer therapy. For example, BRAF inhibitors (like vemurafenib) are used in treating melanoma with BRAF mutations.
Altered Expression Levels:
Overexpression: Many cancers exhibit overexpression of MAPK pathway components, such as RAS, BRAF, and MEK. This overexpression can lead to increased signaling activity, promoting cell proliferation and survival.
Downregulation: In some cases, negative regulators of the MAPK pathway (e.g., MAPK phosphatases) may be downregulated, leading to enhanced MAPK signaling.
The expression levels of MAPK pathway components can serve as biomarkers for cancer diagnosis, prognosis, and treatment response. For example, high levels of phosphorylated ERK (p-ERK) may indicate active MAPK signaling and poor prognosis in certain cancers.

Numerous reports indicate that the MAPK pathway plays a major role in tumor progression and invasion, while inhibition of MAPK signaling reduces invasion.


RCC, Renal cell Carcinoma: Click to Expand ⟱
Renal cell carcinoma (RCC) is one of the most common malignant tumors of the urinary system, accounting for 80–90% of kidney neoplasms.
The activation of the mTOR pathway has been found in RCC and is correlated with high grade and poor prognostic patient features (41,42).


Scientific Papers found: Click to Expand⟱
6018- CGA,    Chlorogenic acid: a review on its mechanisms of anti-inflammation, disease treatment, and related delivery systems
- Review, Var, NA - Review, RCC, NA
*BioAv↓, *Inflam↓, *TNF-α↓, *NO↓, *COX2↓, *PGE2↓, *NF-kB↓, *IL6↓, *IL1β↓, *TLR2↓, *MAPK↓, *NRF2↓, *HO-1↑, *NQO1↑, *cardioP↑, *neuroP↑, *SOD↑, *GSH↑, *ROS↓, *LDH↓, *MDA↓, *cognitive↑, *eff↑,

Showing Research Papers: 1 to 1 of 1

* indicates research on normal cells as opposed to diseased cells
Total Research Paper Matches: 1

Pathway results for Effect on Cancer / Diseased Cells:


Total Targets: 0

Pathway results for Effect on Normal Cells:


Redox & Oxidative Stress

GSH↑, 1,   HO-1↑, 1,   MDA↓, 1,   NQO1↑, 1,   NRF2↓, 1,   ROS↓, 1,   SOD↑, 1,  

Core Metabolism/Glycolysis

LDH↓, 1,  

Cell Death

MAPK↓, 1,  

Angiogenesis & Vasculature

NO↓, 1,  

Immune & Inflammatory Signaling

COX2↓, 1,   IL1β↓, 1,   IL6↓, 1,   Inflam↓, 1,   NF-kB↓, 1,   PGE2↓, 1,   TLR2↓, 1,   TNF-α↓, 1,  

Drug Metabolism & Resistance

BioAv↓, 1,   eff↑, 1,  

Clinical Biomarkers

IL6↓, 1,   LDH↓, 1,  

Functional Outcomes

cardioP↑, 1,   cognitive↑, 1,   neuroP↑, 1,  
Total Targets: 25

Scientific Paper Hit Count for: MAPK, mitogen-activated protein kinase
Query results interpretion may depend on "conditions" listed in the research papers.
Such Conditions may include : 
  -low or high Dose
  -format for product, such as nano of lipid formations
  -different cell line effects
  -synergies with other products 
  -if effect was for normal or cancerous cells
Filter Conditions: Pro/AntiFlg:%  IllCat:%  CanType:24  Cells:%  prod#:%  Target#:181  State#:%  Dir#:1
wNotes=0 sortOrder:rid,rpid

 

Home Page